Delivery Order SPE2DB24D1205-SPE2DB25FCWAY
- Not listed
- AmerisourceBergen Drug Corp has been awarded a delivery order valued at $17,777.00 for 100 mg vials of Enhertu, a oncology therapeutic agent used in cancer treatment. This firm fixed-price, competitively awarded contract was issued by the Defense Logistics Agency Medical Supply Chain on August 14, 2025, with a completion date of September 5, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $14,221.60 on June 30, 2025, for the supply of Enhertu 100 mg vials with an ultimate completion date of July 22, 2025. This firm fixed-price, non-set-aside delivery order represents a pediatric-focused pharmaceutical procurement supporting federal medical supply requirements. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Enhertu 100 mg vials, valued at $17,777.00, with a completion date of September 23, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $17,777.00 delivery order to AmerisourceBergen Drug Corp for 100 milligram vials of Enhertu, a specialty oncology medication. This firm fixed price contract, issued on May 30, 2025, with an ultimate completion date of June 23, 2025, represents a child order under AmerisourceBergen's larger pharmaceutical supply agreements with the federal government. The award was competitively granted without set-aside provisions and will be performed at...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, has been awarded a delivery order valued at $7,110.80 by the Defense Logistics Agency for 100 milligram vials of Enhertu, a prescription oncology medication. The contract, awarded on August 26, 2025, with completion targeted for September 17, 2025, is structured as a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded through open...
- The Defense Logistics Agency awarded a delivery order valued at $17,777.00 to AmerisourceBergen Drug Corp for 100 mg vials of Enhertu, a cancer therapeutic agent. This firm fixed price delivery order was competitively awarded without set-aside designation and is scheduled for completion by September 5, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a leading...
- The Defense Logistics Agency awarded a delivery order valued at $8,888.50 to AmerisourceBergen Drug Corp for the supply of Enhertu 100 mg vials, with an ultimate completion date of October 7, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded on September 16, 2025. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $8,888.50 to AmerisourceBergen Drug Corp for the supply of Enhertu 100 mg vials, with an ultimate completion date of October 9, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded to the prime contractor. The order will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. This delivery order is issued...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $17,777.00 to supply 100 mg vials of Enhertu, a prescription oncology medication, with an ultimate completion date of September 15, 2025. This non-set-aside delivery order employs firm fixed pricing and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, one of the nation's largest pharmaceutical distributors, was competitively...
- The Defense Logistics Agency awarded a delivery order valued at $7,110.80 to AmerisourceBergen Drug Corp for 100 mg vials of Enhertu, a prescription oncology medication used in cancer treatment. This firm fixed-price delivery order, issued on September 5, 2025, with completion targeted for September 26, 2025, represents a non-competitive award under AmerisourceBergen's existing contract vehicle. The product will be delivered to the company's headquarters in Conshohocken, Pennsylvania. This award...
- SPE2DB24D1205Indefinite Delivery Contract
- SPE2DB24D1205-SPE2DB25FCWAYDelivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $12,443.90 for 100 mg vials of Enhertu, a oncology therapeutic agent, with performance in Conshohocken, Pennsylvania and completion scheduled for May 13, 2025. This competitively awarded, firm fixed-price delivery order contains no set-aside designation and represents a child contract under AmerisourceBergen's larger pharmaceutical supply framework with the federal government. This delivery order executes under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including support to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. AmerisourceBergen's extensive federal contract portfolio and demonstrated capability to fulfill specialized pharmaceutical procurement requirements positioned the company to supply this oncology medication through open competition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.4k | 4/22/25 |